IDS and mucopolysaccharidosis: Advances in DNA technology over the past several decades have resulted in the development of enzyme replacement therapy (ERT) for MPS, which was approved by the FDA in April 2003 for MPS I (Aldurazyme®; laronidase), May 2005 for MPS VI (Naglazyme®; galsulfase), July 2006 for MPS II (Elaprase®; idursulfase), and February 2014 for MPS IVA (elosulfase alfa).